<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39142283</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6605</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>American journal of human genetics</Title><ISOAbbreviation>Am J Hum Genet</ISOAbbreviation></Journal><ArticleTitle>Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel.</ArticleTitle><Pagination><StartPage>2044</StartPage><EndPage>2058</EndPage><MedlinePgn>2044-2058</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajhg.2024.07.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9297(24)00257-X</ELocationID><Abstract><AbstractText>The ENIGMA research consortium develops and applies methods to determine clinical significance of variants in hereditary breast and ovarian cancer genes. An ENIGMA BRCA1/2 classification sub-group, formed in 2015 as a ClinGen external expert panel, evolved into a ClinGen internal Variant Curation Expert Panel (VCEP) to align with Food and Drug Administration recognized processes for ClinVar contributions. The VCEP reviewed American College of Medical Genetics and Genomics/Association of Molecular Pathology (ACMG/AMP) classification criteria for relevance to interpreting BRCA1 and BRCA2 variants. Statistical methods were used to calibrate evidence strength for different data types. Pilot specifications were tested on 40 variants and documentation revised for clarity and ease of use. The original criterion descriptions for 13 evidence codes were considered non-applicable or overlapping with other criteria. Scenario of use was extended or re-purposed for eight codes. Extensive analysis and/or data review informed specification descriptions and weights for all codes. Specifications were applied to pilot variants with pre-existing ClinVar classification as follows: 13 uncertain significance or conflicting, 14 pathogenic and/or likely pathogenic, and 13 benign and/or likely benign. Review resolved classification for 11/13 uncertain significance or conflicting variants and retained or improved confidence in classification for the remaining variants. Alignment of pre-existing ENIGMA research classification processes with ACMG/AMP classification guidelines highlighted several gaps in the research processes and the baseline ACMG/AMP criteria. Calibration of evidence strength was key to justify utility and strength of different data types for gene-specific application. The gene-specific criteria demonstrated value for improving ACMG/AMP-aligned classification of BRCA1 and BRCA2 variants.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parsons</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. Electronic address: michael.parsons@qimrberghofer.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Hoya</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Oncology Laboratory, Hospital Cl&#xed;nico San Carlos, IdISSC, 28040 Madrid Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Marcy E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tudini</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Invitae Corporation, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berkofsky-Fessler</LastName><ForeName>Windy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>GeneDx, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Sandrine M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Institut Curie, and Paris Sciences Lettres Research University, 75005 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Raymond C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Color Health, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cline</LastName><ForeName>Melissa S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>UC Santa Cruz Genomics Institute, Genomics, University of California, 1156 High Street, Santa Cruz, CA 95064, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Bing-Jian</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuno</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Garcia</LastName><ForeName>Encarna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadler</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiraki</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GeneDx, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holdren</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houdayer</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Genetics, FHU G4 G&#xe9;nomique, F-76000 Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hruska</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>GeneDx, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>Rachid</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Huei San</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Rouen Normandie, Inserm U1245, F-76000 Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mensenkamp</LastName><ForeName>Arjen R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteiro</LastName><ForeName>Alvaro N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Cancer Epidemiology, H Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathan</LastName><ForeName>Vaishnavi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Color Health, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Inge Sokilde</ForeName><Initials>IS</Initials><AffiliationInfo><Affiliation>Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pesaran</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radice</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Predictive Medicine: Molecular Bases of Genetic Risk, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Venezian 1, 20133 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, Hannover Medical School, 30625 Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southey</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia; Department of Clinical Pathology, The Melbourne Medical School, The University of Melbourne, Melbourne, VIC 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavtigian</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Bryony A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Pathology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toland</LastName><ForeName>Amanda E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH 43210, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turnbull</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Maartje J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Amsterdam University Medical Centers, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weyandt</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ambry Genetics Corporation, Aliso Viejo, CA 92656, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiggins</LastName><ForeName>George A R</ForeName><Initials>GAR</Initials><AffiliationInfo><Affiliation>Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zec</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Natera, Inc, San Carlos, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couch</LastName><ForeName>Fergus J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Logan C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vreeswijk</LastName><ForeName>Maaike P G</ForeName><Initials>MPG</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldgar</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spurdle</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia. Electronic address: amanda.spurdle@qimrberghofer.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 CA116201</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA264971</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 CA253187</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 CA258058</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Hum Genet</MedlineTA><NlmUniqueID>0370475</NlmUniqueID><ISSNLinking>0002-9297</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024682">BRCA2 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C551750">BRCA2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024682" MajorTopicYN="Y">BRCA2 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019313" MajorTopicYN="Y">BRCA1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="Y">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACMG/AMP variant curation guidelines</Keyword><Keyword MajorTopicYN="N">BRCA1</Keyword><Keyword MajorTopicYN="N">BRCA2</Keyword><Keyword MajorTopicYN="N">ClinGen</Keyword><Keyword MajorTopicYN="N">ClinVar</Keyword><Keyword MajorTopicYN="N">VCEP</Keyword></KeywordList><CoiStatement>Declaration of interests M.A. was a paid employee of Invitae. R.C.C. and R.O. are paid employees of Color Health. M.E.R., T.P., and R.K. are paid employees of Ambry Genetics. A.R.M. and M.J.V. received funds from AstraZeneca for contribution to sponsored quality assessments and variant interpretation of BRCA1 and BRCA2 VUS (funds paid to the institution).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>7</Day><Hour>14</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39142283</ArticleId><ArticleId IdType="pmc">PMC11393667</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2024.07.013</ArticleId><ArticleId IdType="pii">S0002-9297(24)00257-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">7545954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524414</ArticleId></ArticleIdList></Reference><Reference><Citation>Spurdle A.B., Healey S., Devereau A., Hogervorst F.B.L., Monteiro A.N.A., Nathanson K.L., Radice P., Stoppa-Lyonnet D., Tavtigian S., Wappenschmidt B., et al. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum. Mutat. 2012;33:2&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240687</ArticleId><ArticleId IdType="pubmed">21990146</ArticleId></ArticleIdList></Reference><Reference><Citation>Caputo S.M., Golmard L., L&#xe9;one M., Damiola F., Guillaud-Bataille M., Revillion F., Rouleau E., Derive N., Buisson A., Basset N., et al. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach. Am. J. Hum. Genet. 2021;108:1907&#x2013;1923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546044</ArticleId><ArticleId IdType="pubmed">34597585</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgar D.E., Easton D.F., Byrnes G.B., Spurdle A.B., Iversen E.S., Greenblatt M.S., IARC Unclassified Genetic Variants Working Group Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum. Mutat. 2008;29:1265&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936773</ArticleId><ArticleId IdType="pubmed">18951437</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgar D.E., Easton D.F., Deffenbaugh A.M., Monteiro A.N.A., Tavtigian S.V., Couch F.J., Breast Cancer Information Core BIC Steering Committee Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet. 2004;75:535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182042</ArticleId><ArticleId IdType="pubmed">15290653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindor N.M., Guidugli L., Wang X., Vall&#xe9;e M.P., Monteiro A.N.A., Tavtigian S., Goldgar D.E., Couch F.J. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS) Hum. Mutat. 2012;33:8&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242438</ArticleId><ArticleId IdType="pubmed">21990134</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson D., Easton D.F., Goldgar D.E. A full-likelihood method for the evaluation of causality of sequence variants from family data. Am. J. Hum. Genet. 2003;73:652&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180690</ArticleId><ArticleId IdType="pubmed">12900794</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehm H.L., Berg J.S., Brooks L.D., Bustamante C.D., Evans J.P., Landrum M.J., Ledbetter D.H., Maglott D.R., Martin C.L., Nussbaum R.L., et al. ClinGen--the Clinical Genome Resource. N.&#xa0;Engl. J. Med. 2015;372:2235&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4474187</ArticleId><ArticleId IdType="pubmed">26014595</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Munoz E.A., Milko L.V., Harrison S.M., Azzariti D.R., Kurtz C.L., Lee K., Mester J.L., Weaver M.A., Currey E., Craigen W., et al. ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. Hum. Mutat. 2018;39:1614&#x2013;1622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6225902</ArticleId><ArticleId IdType="pubmed">30311389</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomassen M., Mesman R.L.S., Hansen T.V.O., Menendez M., Rossing M., Esteban-S&#xe1;nchez A., Tudini E., T&#xf6;rngren T., Parsons M.T., Pedersen I.S., et al. Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach. Hum. Mutat. 2022;43:1921&#x2013;1944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10946542</ArticleId><ArticleId IdType="pubmed">35979650</ArticleId></ArticleIdList></Reference><Reference><Citation>James P.A., Fortuno C., Li N., Lim B.W.X., Campbell I.G., Spurdle A.B. Estimating the proportion of pathogenic variants from breast cancer case-control data: Application to calibration of ACMG/AMP variant classification criteria. Hum. Mutat. 2022;43:882&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">35191126</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons M.T., Tudini E., Li H., Hahnen E., Wappenschmidt B., Feliubadal&#xf3; L., Aalfs C.M., Agata S., Aittom&#xe4;ki K., Alducci E., et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Hum. Mutat. 2019;40:1557&#x2013;1578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772163</ArticleId><ArticleId IdType="pubmed">31131967</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahony D.G., Ramus S.J., Southey M.C., Meagher N.S., Hadjisavvas A., John E.M., Hamann U., Imyanitov E.N., Andrulis I.L., Sharma P., et al. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. Br. J. Cancer. 2023;128:2283&#x2013;2294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10241792</ArticleId><ArticleId IdType="pubmed">37076566</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavtigian S.V., Greenblatt M.S., Harrison S.M., Nussbaum R.L., Prabhu S.A., Boucher K.M., Biesecker L.G., ClinGen Sequence Variant Interpretation Working Group ClinGen SVI Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet. Med. 2018;20:1054&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336098</ArticleId><ArticleId IdType="pubmed">29300386</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiffin N., Minikel E., Walsh R., O'Donnell-Luria A.H., Karczewski K., Ing A.Y., Barton P.J.R., Funke B., Cook S.A., MacArthur D., Ware J.S. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet. Med. 2017;19:1151&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563454</ArticleId><ArticleId IdType="pubmed">28518168</ArticleId></ArticleIdList></Reference><Reference><Citation>Pejaver V., Byrne A.B., Feng B.J., Pagel K.A., Mooney S.D., Karchin R., O'Donnell-Luria A., Harrison S.M., Tavtigian S.V., Greenblatt M.S., et al. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria. Am. J. Hum. Genet. 2022;109:2163&#x2013;2177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9748256</ArticleId><ArticleId IdType="pubmed">36413997</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker L.C., Hoya M.d.l., Wiggins G.A.R., Lindy A., Vincent L.M., Parsons M.T., Canson D.M., Bis-Brewer D., Cass A., Tchourbanov A., et al. Using the ACMG/AMP framework to capture evidence related to predicted and observed impact on splicing: Recommendations from the ClinGen SVI Splicing Subgroup. Am. J. Hum. Genet. 2023;110:1046&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10357475</ArticleId><ArticleId IdType="pubmed">37352859</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum M.J., Lee J.M., Riley G.R., Jang W., Rubinstein W.S., Church D.M., Maglott D.R. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980&#x2013;D985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965032</ArticleId><ArticleId IdType="pubmed">24234437</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuno C., Michailidou K., Parsons M., Dolinsky J.S., Pesaran T., Yussuf A., Mester J.L., Hruska K.S., O&#x2019;Connor R., O'Connor R., et al. Challenges and approaches to calibrating patient phenotype as evidence for cancer gene variant classification under ACMG/AMP guidelines. Hum. Mol. Genet. 2024;33:724&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11000651</ArticleId><ArticleId IdType="pubmed">38271184</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng B.J. PERCH: A Unified Framework for Disease Gene Prioritization. Hum. Mutat. 2017;38:243&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299048</ArticleId><ArticleId IdType="pubmed">27995669</ArticleId></ArticleIdList></Reference><Reference><Citation>Belman S., Parsons M.T., Spurdle A.B., Goldgar D.E., Feng B.J. Considerations in assessing germline variant pathogenicity using cosegregation analysis. Genet. Med. 2020;22:2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pubmed">32773770</ArticleId></ArticleIdList></Reference><Reference><Citation>Breast Cancer Association Consortium. Dorling L., Carvalho S., Allen J., Gonz&#xe1;lez-Neira A., Luccarini C., Wahlstr&#xf6;m C., Pooley K.A., Parsons M.T., Fortuno C., et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N.&#xa0;Engl. J. Med. 2021;384:428&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611105</ArticleId><ArticleId IdType="pubmed">33471991</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavtigian S.V., Harrison S.M., Boucher K.M., Biesecker L.G. Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum. Mutat. 2020;41:1734&#x2013;1737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011844</ArticleId><ArticleId IdType="pubmed">32720330</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou Tayoun A.N., Pesaran T., DiStefano M.T., Oza A., Rehm H.L., Biesecker L.G., Harrison S.M., ClinGen Sequence Variant Interpretation Working Group ClinGen SVI Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum. Mutat. 2018;39:1517&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6185798</ArticleId><ArticleId IdType="pubmed">30192042</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Hoya M., Soukarieh O., L&#xf3;pez-Perolio I., Vega A., Walker L.C., van Ierland Y., Baralle D., Santamari&#xf1;a M., Lattimore V., Wijnen J., et al. Combined genetic and splicing analysis of BRCA1 c.[594-2A&gt;C; 641A&gt;G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum. Mol. Genet. 2016;25:2256&#x2013;2268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081057</ArticleId><ArticleId IdType="pubmed">27008870</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A.L., Leonard C., Koufariotis L.T., Parsons M.T., Hollway G.E., Pearson J.V., Newell F., Waddell N., Spurdle A.B. Considerations for using population frequency data in germline variant interpretation: Cancer syndrome genes as a model. Hum. Mutat. 2021;42:530&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">33600021</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X., Maciaszek J.L., Thompson B.A., Leong H.S., Dixon K., Sousa S., Anderson M., Roberts M.E., Lee K., Spurdle A.B., et al. Optimising clinical care through CDH1-specific germline variant curation: improvement of clinical assertions and updated curation guidelines. J.&#xa0;Med. Genet. 2023;60:568&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10202836</ArticleId><ArticleId IdType="pubmed">36600593</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A.L., Michailidou K., Parsons M.T., Fortuno C., Bolla M.K., Wang Q., Dennis J., Naven M., Abubakar M., Ahearn T.U., et al. Co-observation of germline pathogenic variants in different breast cancer predisposition genes: results from analysis of the BRIDGES sequencing dataset. Am. J. Hum. Genet. 2024;111:2059&#x2013;2069.</Citation><ArticleIdList><ArticleId IdType="pubmed">39096911</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston C.G., Wright M.W., Madhavrao R., Harrison S.M., Goldstein J.L., Luo X., Wand H., Wulf B., Cheung G., Mandell M.E., et al. ClinGen Variant Curation Interface: a variant classification platform for the application of evidence criteria from ACMG/AMP guidelines. Genome Med. 2022;14:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8764818</ArticleId><ArticleId IdType="pubmed">35039090</ArticleId></ArticleIdList></Reference><Reference><Citation>Cline M.S., Liao R.G., Parsons M.T., Paten B., Alquaddoomi F., Antoniou A., Baxter S., Brody L., Cook-Deegan R., Coffin A., et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324924</ArticleId><ArticleId IdType="pubmed">30586411</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>